Trends in zidovudine prescription for pregnant women infected with HIV

被引:11
作者
Lansky, A
Jones, JL
Wan, PCT
Lindegren, ML
Wortley, P
机构
[1] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA
[3] TRW Co Inc, Syst Integrat Grp, Atlanta, GA USA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1998年 / 18卷 / 03期
关键词
AIDS; HIV; pregnancy; zidovudine; women;
D O I
10.1097/00042560-199807010-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The purpose of this analysis was to describe trends in zidovudine prescription during pregnancy among women infected with HIV. Methods: We used data from the Adult and Adolescent Spectrum of Disease Surveillance Project, which collects information on HIV-related conditions through medical record review. Women who were reported pregnant from 1990 through 1996 were included in the analysis. Results: From 1990 through 1996, of 7047 women in the project, 711 (10%) were pregnant for a total of 782 pregnancies. We found a high proportion (82%) of pregnancies during which zidovudine was prescribed for women with CD4+ T-lymphocyte count of 0 to 199 cells/mu l (n = 125), but no trend over time. In contrast, from 1990 through 1996 zidovudine was prescribed for an increasing proportion of pregnancies in which the woman's CD4+ count was 200 to 499 cells/mu l (62%-78%; p = .01; n = 337) and greater than or equal to 500 cells/mu l (22%-55%; p = .001; n = 250). Conclusions: Our study demonstrated differences in zidovudine prescription over time by CD4+ count; these differences may be based on the woman's health and guidelines for perinatal prevention.
引用
收藏
页码:289 / 292
页数:4
相关论文
共 16 条
[1]  
[Anonymous], 1994, MMWR Recomm Rep, V43, P1
[2]   FACTORS PREDICTIVE OF MATERNAL-FETAL TRANSMISSION OF HIV-1 - PRELIMINARY-ANALYSIS OF ZIDOVUDINE GIVEN DURING PREGNANCY AND/OR DELIVERY [J].
BOYER, PJ ;
DILLON, M ;
NAVAIE, M ;
DEVEIKIS, A ;
KELLER, M ;
OROURKE, S ;
BRYSON, YJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24) :1925-1930
[3]  
*CDCP, 1996, HIV AIDS SURVEILANCE, V8, P32
[4]  
*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43
[5]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1005
[6]   After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants [J].
Cooper, ER ;
Nugent, RP ;
Diaz, C ;
Pitt, J ;
Hanson, C ;
Kalish, LA ;
Mendez, H ;
Zorrilla, C ;
Hershow, R ;
Moye, J ;
Smeriglio, V ;
Fowler, MG ;
Rich, K ;
Turpin, D ;
PachecoAcosta, E ;
Tuomala, R ;
Mesthene, D ;
Fox, H ;
Higgins, A ;
Landesman, S ;
Moroso, G ;
Willoughby, A ;
Sheon, A ;
McKinlay, S ;
Sherrieb, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1207-1211
[7]  
*DHHS, 1997, FED REGISTER, V62, P36809
[8]   Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission - Effect of maternal zidovudine treatment on viral load [J].
Dickover, RE ;
Garratty, EM ;
Herman, SA ;
Sim, MS ;
Plaeger, S ;
Boyer, PJ ;
Keller, M ;
Deveikis, A ;
Stiehm, ER ;
Bryson, YJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (08) :599-605
[9]   SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES [J].
FARIZO, KM ;
BUEHLER, JW ;
CHAMBERLAND, ME ;
WHYTE, BM ;
FROELICHER, ES ;
HOPKINS, SG ;
REED, CM ;
MOKOTOFF, ED ;
COHN, DL ;
TROXLER, S ;
PHELPS, AF ;
BERKELMAN, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (13) :1798-1805
[10]  
Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483